Moreover, the 36-month beta value for OPRX is 1.37. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for OPRX is 15.73M and currently, short sellers hold a 7.85% of that float. On January 22, 2025, OPRX’s average trading volume was 303.54K shares.
OPRX) stock’s latest price update
The stock of OptimizeRx Corp (NASDAQ: OPRX) has increased by 12.59 when compared to last closing price of 4.80.Despite this, the company has seen a gain of 11.55% in its stock price over the last five trading days. globenewswire.com reported 2024-12-23 that WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that William J. Febbo, Chief Executive Officer (CEO) and Board Member, will be departing the Company, effective as of December 31, 2024, to pursue other opportunities. Mr. Febbo will provide the Company with advisory services through March 31, 2025. The Company’s Board of Directors has retained a search firm to assist in this transition.
OPRX’s Market Performance
OPRX’s stock has risen by 11.55% in the past week, with a monthly rise of 3.44% and a quarterly drop of -18.03%. The volatility ratio for the week is 7.15% while the volatility levels for the last 30 days are 9.36% for OptimizeRx Corp The simple moving average for the past 20 days is 5.64% for OPRX’s stock, with a -34.32% simple moving average for the past 200 days.
Analysts’ Opinion of OPRX
Many brokerage firms have already submitted their reports for OPRX stocks, with RBC Capital Mkts repeating the rating for OPRX by listing it as a “Sector Perform.” The predicted price for OPRX in the upcoming period, according to RBC Capital Mkts is $6 based on the research report published on January 08, 2025 of the current year 2025.
Stephens, on the other hand, stated in their research note that they expect to see OPRX reach a price target of $5.50. The rating they have provided for OPRX stocks is “Equal-Weight” according to the report published on December 20th, 2024.
B. Riley Securities gave a rating of “Buy” to OPRX, setting the target price at $18.50 in the report published on July 25th of the previous year.
OPRX Trading at 5.23% from the 50-Day Moving Average
After a stumble in the market that brought OPRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.50% of loss for the given period.
Volatility was left at 9.36%, however, over the last 30 days, the volatility rate increased by 7.15%, as shares surge +13.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.87% upper at present.
During the last 5 trading sessions, OPRX rose by +11.55%, which changed the moving average for the period of 200-days by -51.57% in comparison to the 20-day moving average, which settled at $5.12. In addition, OptimizeRx Corp saw 11.32% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OPRX starting from FEBBO WILLIAM J, who purchase 20,000 shares at the price of $5.01 back on Dec 12 ’24. After this action, FEBBO WILLIAM J now owns 601,253 shares of OptimizeRx Corp, valued at $100,220 using the latest closing price.
Stock Fundamentals for OPRX
Current profitability levels for the company are sitting at:
- -0.32 for the present operating margin
- 0.61 for the gross margin
The net margin for OptimizeRx Corp stands at -0.27. The total capital return value is set at -0.19. Equity return is now at value -20.97, with -16.72 for asset returns.
Based on OptimizeRx Corp (OPRX), the company’s capital structure generated 0.24 points at debt to capital in total, while cash flow to debt ratio is standing at -0.04. The debt to equity ratio resting at 0.31. The interest coverage ratio of the stock is -4.67.
Currently, EBITDA for the company is -21.31 million with net debt to EBITDA at -0.85. When we switch over and look at the enterprise to sales, we see a ratio of 1.35. The receivables turnover for the company is 3.35for trailing twelve months and the total asset turnover is 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.23.
Conclusion
To wrap up, the performance of OptimizeRx Corp (OPRX) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
